Tagadherence

Study finds previously incarcerated women with HIV less likely to adhere to treatment

S

British Columbia Centre for Excellence in HIV/AIDS, July 19, 2016 The British Columbia Centre for Excellence in HIV/AIDS (BCCfE) has released new research that finds previously incarcerated women with HIV are three times more likely to have poor adherence to combination anti-retroviral therapy than HIV positive women who have not been incarcerated. Simon Fraser University Health Sciences...

Uptake of long-acting, reversible contraception in three remote Aboriginal communities: a population-based study

U

Med J Aust 2016; 205 (1): 21-25. doi: 10.5694/mja16.00073 Objective: To assess the use, effectiveness and acceptance of prescribed contraception in three remote Western Australian Aboriginal communities Conclusion: The high uptake of LARCs in these communities is consistent with international recommendations about contraception use. High acceptability was reflected in excellent continuation rates...

Bobby Goldsmith Foundation financial support for PLHIV in SA

B

Living with HIV can be stressful and isolating. Bobby Goldsmith Foundation is here to help. Now with a base in Adelaide, BGF can provide direct financial support for people living with HIV (PLHIV) in South Australia to help people manage the cost of their health. BGF works to ensure PLHIV have access to treatments and can remain adherent to vital medications. If you are living with HIV and on low...

Contraception for women with epilepsy: counselling, choices, and concerns

C

Open Access Journal of Contraception, 19 April 2016 Volume 2016:7 Pages 69—76 Arne Reimers, Department of Clinical Pharmacology, St Olavs University Hospital, and Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway Abstract: Approximately 50% of all pregnancies in women with epilepsy (WWE)...

New PrEP studies will be a challenge, statisticians warn

N

nam/aidsmap, Published: 26 January 2016 Two statisticians involved in the PROUD and iPrEx trials of pre-exposure prophylaxis (PrEP) warn that future trials to test new PrEP drugs and formulations may be extremely difficult to design. David Dunn of the UK Medical Research Council and David Glidden of the University of California, San Francisco say that statisticians will need to choose and analyse...

Your sidebar area is currently empty. Hurry up and add some widgets.